Combination therapy for renal cell cancer: What are possible options?

Oncology

Volumn 81, Issue 3-4, 2011, Pages 220-229

  Santos, Napoleon ^a   Wenger, Justin B ^a   Havre, Pamela ^a   Liu, Yanxia ^c   Dagan, Roi ^b   Imanirad, Iman ^a   Ivey, Alison M ^a   Zlotecki, Robert A ^b   Algood, Chester B ^c   Gilbert, Scott M ^c   Allegra, Carmen J ^a   Okunieff, Paul ^b   Vieweg, Johannes ^c   Dang, Nam H ^a   Luesch, Hendrik ^c   Dang, Long H ^a,d  

^a Hematology and Medical Oncology   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d NONE   (United States)

Author keywords

Antiangiogenic therapy; Hypoxia inducible factor 1 ; Hypoxia inducible factor 2 ; mTOR; Multikinase inhibitor; Renal cell cancer

Indexed keywords

AXITINIB; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; PAZOPANIB; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB;

ANTIANGIOGENIC THERAPY; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; OVERALL SURVIVAL; PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMATITIS; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 80855144261     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000333470     Document Type: Review

References (65)

1. American Cancer Society: Cancer Facts and Figures 2011. Atlanta, American Cancer Society, 2011.
2. Kumar V, Abbas AK, Fausto N: Robbins & Cotran Pathologic Basis of Disease, ed 7. Elsevier, 2005
3. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
4. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
5. Kerbel RS: Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000; 21: 505-515.
6. Gale NW, Thurston G, Davis S, Wiegand SJ, Holash J, Rudge JS, Yancopoulos GD: Complementary and coordinated roles of the VEGFs and angiopoietins during normal and pathologic vascular formation. Cold Spring Harb Symp Quant Biol 2002; 67: 267-273.
7. Jain RK, Duda DG, Clark JW, Loeffler JS: Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
8. Chow LQ, Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007; 25: 884-896.
9. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
10. Bukowski RM: New antiangiogenic agents for renal cell carcinoma: Bevacizumab. Curr Oncol Rep 2004; 6: 85-86.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
12. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068.
13. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
14. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111.
15. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26: 5422-5428.
16. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143.
17. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, et al: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-3714.
18. Sosman JA, Flaherty KT, Atkins MB, Mc-Dermott DF, Rothenberg ML, Vermeulen WL, et al: Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008; 26(May 20 suppl):abstract 5011.
19. Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R: Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010; 28: 2131-2136.
20. Medioni J, Banu E, Helley D, Scotte F, Fournier L, Mejean A, et al: Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: A case series. Eur Urol 2009; 56: 207-211, quiz 211.
21. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al: Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 1432-1439.
22. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, et al: Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol 2010; 28:e284-e285, author reply e286-e287.
23. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005; 23: 7889-7896.
24. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, et al: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007; 25: 4536-4541.
25. Hainsworth JD, Spigel DR, Sosman JA, Burris HA 3rd, Farley C, Cucullu H, et al: Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/ imatinib: A phase I/II trial. Clin Genitourin Cancer 2007; 5: 427-432.
26. Escudier BJ, Negrier S, Gravis G, Chevreau C, Delva R, Bay J, et al: Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial (abstract 4516). J Clin Oncol 2010; 28(suppl):15s.
27. Escudier B, Kataja V: Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(suppl 4):81-82.
28. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
29. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
30. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, et al: Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 4068-4075.
31. Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, et al: Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial. J Clin Oncol 2011; 29(suppl 7);abstract LBA308.
32. Kroog GS, Feldman DR, Kondagunta GV, Ginsberg MS, Fischer PM, Trinos MJ, et al: Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma (abstract 5037). J Clin Oncol 2009; 27(suppl):15s.
33. Patel PH, Senico PL, Curiel RE, Motzer RJ: Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 24-27.
34. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, et al: A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011; 117: 4194-4200.
35. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, et al: Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 475-480.
36. Nosov D, Bhargava P, Esteves WB, Strahs AL, Lipatov ON, Lyulko OO, et al: Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). J Clin Oncol 2011; 29 (suppl);abstract 4550.
37. Blagosklonny MV: Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-17.
38. Folkman J: A novel anti-vascular therapy for cancer. Cancer Biol Ther 2004; 3: 338-339.
39. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309.
40. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
41. Burkitt K, Chun SY, Dang DT, Dang LH: Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 2009; 8: 1148-1156.
42. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
43. Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH: Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1a and HIF-2a target genes. Mol Cancer 2010; 9: 293.
44. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, et al: The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 2003; 22: 3213-3220.
45. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, et al: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93: 309-314.
46. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al: Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 2002; 8: 1831-1837.
47. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos C, Turley H, Talks K, et al: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-andneck cancer. Int J Radiat Oncol Biol Phys 2002; 53: 1192-1202.
48. Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al: Expression of hypoxia-inducible factor-1alpha: A novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-2916.
49. Kurokawa T, Miyamoto M, Kato K, Cho Y, Kawarada Y, Hida Y, et al: Overexpression of hypoxia-inducible-factor 1alpha (HIF-1-alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer 2003; 89: 1042-1047.
50. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G: Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-4696.
51. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G: Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: Its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7: 1661-1668.
52. Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, et al: Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer 2001; 92: 165-171.
53. Bachtiary B, Schindl M, Potter R, Dreier B, Knocke TH, Hainfellner JA, et al: Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003; 9: 2234-2240.
54. Rini BI, Atkins MB: Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000.
55. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al: Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009; 8: 1867-1877.
56. Semenza GL: HIF-1 inhibitors for cancer therapy: From gene expression to drug discovery. Curr Pharm Des 2009; 15: 3839-3843.
57. Melillo G: Hypoxia-inducible factor 1 inhibitors. Methods Enzymol 2007; 435: 385-402.
58. Escuin D, Simons JW, Giannakakou P: Exploitation of the HIF axis for cancer therapy. Cancer Biol Ther 2004; 3: 608-611.
59. Giaccia A, Siim BG, Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-811.
60. Chun SY, Johnson C, Washburn JG, Cruz-Correa MR, Dang DT, Dang LH: Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1 - and HIF-2 - target genes. Mol Cancer 2010; 9: 293.
61. Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK, Gardner KH: Artificial ligand binding within the HIF2alpha PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci USA 2009; 106: 450-455.
62. Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, et al: Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 28-33.
63. Ryan CW, Goldman BH, Lara PN Jr, Mack PC, Beer TM, Tangen CM, et al: Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: A phase II study of the Southwest Oncology Group. J Clin Oncol 2007; 25: 3296-3301.
64. Gollob JA, Rathmell WK, Richmond TM, Marino CB, Miller EK, Grigson G, et al: Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol 2007; 25: 3288-3295.
65. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, et al: Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: The ROSORC trial. Br J Cancer 2011; 104: 1256-1261.